Primum non nocere—first, do no harm with bariatric surgery

Karl J. Neff, Carel W. le Roux

    Research output: Contribution to journalComment/debatepeer-review

    2 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)476-477
    Number of pages2
    JournalThe Lancet Diabetes and Endocrinology
    Volume9
    Issue number8
    DOIs
    Publication statusPublished - Aug 2021

    Bibliographical note

    Funding Information:
    CWlR serves on advisory boards for Novo Nordisk, Johnson & Johnson, and Herbalife; has received grant funding (to his institution) from the Irish Research Council, the Science Foundation Ireland, the Innovative Medicines Initiative of the EU, and the Health Research Board Ireland; has received honoraria, or payments for lectures, speakers bureaus, presentations, or education events, from Novo Nordisk, Johnson & Johnson, and Herbalife; has received financial support for attendance at educational events or travel from Novo Nordisk, Johnson & Johnson, and Herbalife; and is a board member of the Irish Society for Nutrition and Metabolism. KJN declares no competing interests.

    Keywords

    • Bariatric Surgery/adverse effects
    • Humans

    Cite this